The enrollment milestone also marks progress in AIM ImmunoTech's broader strategy to advance Ampligen toward late-stage development in pancreatic cancer. The company said it is continuing Phase 3 ...
AIM ImmunoTech Inc. (AIM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
AIM ImmunoTech Inc. (AIM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results